21 Analysts Have This to Say About Apellis Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 21 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. The analysts have an average price target of $65.0 versus the current price of Apellis Pharmaceuticals at $51.075, implying an upside. This current average has increased by 16.42% from the previous average price target of $55.83.
November 02, 2023 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
21 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock over the past 3 months, with an average price target of $65.0, implying an upside. This current average has increased by 16.42% from the previous average price target of $55.83.
The average price target given by the analysts is higher than the current price of Apellis Pharmaceuticals, implying an upside. This is a positive signal for the stock. Moreover, the average price target has increased by 16.42% from the previous average price target, indicating growing confidence among analysts about the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100